Clinical Study on Anti-PD-1 Plus Lenalidomide and Azacitidine in Relapsed/Refractory Peripheral T-cell Lymphoma
Status:
Recruiting
Trial end date:
2022-12-14
Target enrollment:
Participant gender:
Summary
Aim of this study will evaluate the Efficacy and Safety of Anti-PD-1 monoclonal antibody
Combined Lenalidomide and Azacitidine in Relapsed/Refractory Peripheral T-cell Lymphoma
Patients.
Phase:
Phase 2
Details
Lead Sponsor:
The First Affiliated Hospital of Soochow University